Use of the BIOMIC Video System to evaluate the susceptibility of clinical yeast isolates to fluconazole and voriconazole by a disk diffusion method.
The ARTEMIS Global Antifungal Susceptibility Program provides the collection of epidemiological data and the results of the fluconazole and voriconazole susceptibility testing of yeast isolates. Participating in this study, a total of 7318 clinical yeast isolates were tested from different geographical areas in Hungary in the period 2001 to 2003. The species isolated most frequently was C. albicans (68.8%), followed by C. glabrata (11.8%), C. tropicalis (5.7%) and C. krusei (4.6%). Isolates of C. albicans, C. kefyr, C. lusitaniae, C. tropicalis and C. parapsilosis were highly susceptible to fluconazole (78.9-100%). The rates of isolation of fluconazole-resistant C. glabrata and C. krusei were higher in our study than the global mean in 2001 (28.2% and 87.5% vs. 18.3% and 70.2%, respectively). Differences were detected in the distribution of fluconazole-susceptibility data of C. glabrata isolates in the different counties of Hungary: most of the resistant isolates were observed in the eastern part of the country.
Dóczi
Ilona
I
Department of Clinical Microbiology, Faculty of Medicine, University of Szeged, Szeged, Hungary.
Mestyán
Gy
G
Puskás
Erzsébet
E
Nikolova
Radka
R
Barcs
I
I
Nagy
Elisabeth
E
D002175:Candida / Q000187:drug effects* / Q000302:isolation & purification; D002177:Candidiasis / Q000382:microbiology; D015725:Fluconazole / Q000494:pharmacology*; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008826:Microbial Sensitivity Tests / Q000379:methods*; D018715:Microscopy, Video / Q000379:methods; D011743:Pyrimidines / Q000494:pharmacology*; D014230:Triazoles / Q000494:pharmacology*; D065819:Voriconazole
D011743:Pyrimidines; D014230:Triazoles; D015725:Fluconazole; D065819:Voriconazole